Biopharma Advances Fueling Enhanced Disease Management

Biopharma Advances Fueling Enhanced Disease Management

RELEASE DATE
10-Nov-2017
REGION
Global
Research Code: D758-00-60-00-00
SKU: HC02920-GL-TA_21093

$250.00

Special Price $187.50 save 25 %

In stock
SKU
HC02920-GL-TA_21093

$250.00

$187.50 save 25 %

DownloadLink

Pay by invoice

ENQUIRE NOW

Description

This edition of the Genetic Technology TOE depicts biopharmaceutical advances fueling enhanced disease management. Big pharma collaborations and ongoing clinical trials are depicted for therapies, including RNAi therapy. Industry influencers for further business development are included.

The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants.

The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.

Keywords: Disease management, gene therapy, cystinosis, tissue engineered blood vessel graft, RNAi therapy, Big Pharma collaboration

Table of Contents

Recent Biopharma Advances

  • Novel Gene Therapy for Cystinosis
  • Novel Tissue-Engineered Blood Vessel Graft
  • Big Pharma Collaboration for RNAi Therapy
  • AvidBiotics Splits to Form Two New Companies

Clinical Trial Analysis and Industry Interactions

  • Summary of Active Clinical Trials Evaluating RNAi Therapy
  • Summary of Key Contacts
Related Research
This edition of the Genetic Technology TOE depicts biopharmaceutical advances fueling enhanced disease management. Big pharma collaborations and ongoing clinical trials are depicted for therapies, including RNAi therapy. Industry influencers for further business development are included. The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants. The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Disease management, gene therapy, cystinosis, tissue engineered blood vessel graft, RNAi therapy, Big Pharma collaboration
More Information
No Index No
Podcast No
Industries Healthcare
WIP Number D758-00-60-00-00
Is Prebook No
Ti Codes D718